As of 2025-10-23, the EV/EBITDA ratio of Sorrento Therapeutics Inc (SRNE) is -0.01. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SRNE's latest enterprise value is 4.41 mil USD. SRNE's TTM EBITDA according to its financial statements is -340.66 mil USD. Dividing these 2 quantities gives us the above SRNE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.8x - 16.7x | 14.5x |
| Forward P/E multiples | 15.0x - 18.3x | 16.4x |
| Fair Price | (9.29) - (10.29) | (9.56) |
| Upside | -116273.4% - -128786.8% | -119633.5% |
| Date | EV/EBITDA |